• 1.

    Brenner S, et al. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 1961;190:576581. doi: 10.1038/190576a0

  • 2.

    Gros F, et al. Unstable ribonucleic acid revealed by pulse labelling of Escherichia coli. Nature 1961; 190:581585. doi: 10.1038/190581a0

  • 3.

    Sahin U, et al. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov 2014; 13:759780. doi: 10.1038/nrd4278

  • 4.

    Karikó K, et al. Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23:165175. doi: 10.1016/j.immuni.2005.06.008

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Moderna. Research: Product pipeline. Accessed November 1, 2022. https://www.modernatx.com/en-US/research/product-pipeline

  • 6.

    Clinicaltrials.gov. Open-Label Study of mRNA-3927 in Participants with Propionic Acidemia. Last updated November 1, 2022. https://clinicaltrials.gov/ct2/show/NCT04159103

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Moderna. mRNA Access: Resources. Accessed November 11, 2022. https://mrna-access.modernatx.com/resources

mRNA-Based Therapeutics Poised to Provide Growing Therapeutic Options

Bridget M. Kuehn
Search for other papers by Bridget M. Kuehn in
Current site
Google Scholar
Restricted access